Galangin Inhibits Programmed Cell Death-Ligand 1 Expression by Suppressing STAT3 and MYC and Enhances T Cell Tumor-Killing Activity.
Yi Zhong,Ming Yue Li,Lizhuo Han,Yi Tai,Shen Cao,Jiaxuan Li,Hanyu Zhao,Run Wang,Baojiang Lv,Zhida Shan,Hong Xiang Zuo,Lianxun Piao,Hong Lan Jin,Yue Xing,Xuejun Jin,Juan Ma
DOI: https://doi.org/10.1016/j.phymed.2023.154877
IF: 6.656
2023-01-01
Phytomedicine
Abstract:BACKGROUND:The flavonoid galangin (3,5,7-trihydroxyflavone) is derived from the root of Alpinia officinarum Hance, an edible and medicinal herb. Galangin has many biological activities, such as anti-inflammatory, anti-microbial, anti-viral, anti-obesogenic, and anti-oxidant effects. However, the anti-tumor mechanism of galangin remains unclear.PURPOSE:To elucidate the anti-tumor mechanisms of galangin in vitro and in vivo.METHODS:MTT, western blotting, immunoprecipitation, RT-PCR, and immunofluorescence assays were used to assess the mechanism of galangin inhibiting PD-L1 expression. The effect of galangin on T cell activity was analyzed in Hep3B/T cell co-cultures. Colony formation, EdU, migration, and invasion assays were performed to explore the effect of galangin on cancer progression and metastasis. Anti-tumor effects of galangin were investigated in a xenograft model.RESULTS:Galangin inhibited PD-L1 expression dose-dependently, which plays a major role in tumor progression. Moreover, galangin blocked STAT3 activation through the JAK1/JAK2/Src signaling pathway and Myc activation through the Ras/RAF/MEK/ERK signaling pathway. Galangin reduced PD-L1 expression by suppressing STAT3 and Myc cooperatively. Galangin increased the killing effect of T cells on tumor cells in Hep3B/T cell co-cultures. Moreover, galangin inhibited tumor cell proliferation, migration, and invasion through PD-L1. In vivo experiments showed that galangin suppressed tumor growth.CONCLUSION:Galangin enhances T-cell activity and inhibits tumor cell proliferation, migration, and invasion through PD-L1. The current study emphasizes the anti-tumor properties of galangin, offering new insights into the development of tumor therapeutics targeting PD-L1.